Key Takeaways
- Thorough DSO due diligence includes financial stability, clinical autonomy protections, deal structure, and post-close reputation before you sell.
- Up to 40% of a DSO deal may be paid in equity, which makes you a partner and investor as well as a seller, so evaluate the organization like a disciplined investor.
- Review the private equity backing, leverage metrics, equity model, and distribution history to gauge whether your rolled equity can deliver meaningful returns.
- Use structured peer due diligence by speaking with dentists who sold 12–24 months ago and asking specific, verifiable questions about staff, operations, and earnout fairness.
- McLerran & Associates provides dental-specific sell-side representation and can guide you through the entire DSO vetting process, helping you protect your equity, staff, and legacy when you talk with a dental-focused advisor about your DSO options.
Why You Must Vet DSOs Like an Investor
Selling to a DSO places you in three roles at once: seller, partner, and investor. The seller role focuses on cash at close, which many doctors understandably prioritize. The partner role centers on what the DSO will do for your staff, patients, and daily operations, which shapes your day-to-day experience. The investor role, which many dentists overlook, carries the greatest financial risk because your rolled equity ties your future returns to the DSO’s overall performance.
As mentioned in the takeaways, up to 40% of a DSO deal can be structured as rollover equity (stock in the DSO itself) rather than cash. If the DSO is undercapitalized, overleveraged, or backed by a private equity fund nearing the end of its investment cycle without a clear exit, that “second bite of the apple” can be worth far less than projected. Higher interest rates and operating costs have led to financial challenges for several DSO groups in recent years, with some transitioning into lender control following restructuring difficulties.
You can reduce this risk by underwriting the DSO the way a disciplined investor would underwrite any private equity investment. That approach includes examining the capital structure, verifying claims in writing, and speaking directly with dentists who have already completed the transition. This guide walks through that process step by step.
Talk to a dental-specific advisor about your DSO due diligence to discuss your practice, your goals, and how to approach DSO vetting with an experienced sell-side advisor on your side.
How to Analyze a DSO’s Private Equity Backing
The financial stability of the private equity firm behind a DSO can be one of the main factors that determines whether your rolled equity ever yields a meaningful return. You can review several key indicators before you sign anything.
Start with the PE fund’s vintage year. A vintage year is the year a private equity fund began investing. Private equity funds typically have a total lifecycle of about 10 years, with a 3–5 year investment period and a 3–7 year harvest period, rather than a single 5–7 year investment cycle. Rollover equity is typically illiquid for about 5–7 years and depends on the whole DSO’s performance rather than the individual practice’s performance. Ask directly in writing: “What fund is backing this DSO, what is its vintage year, and when is the next recapitalization expected?”
Next, request leverage metrics. Once you know the fund’s timing, you can assess its risk profile. The debt-to-equity ratio measures how much of a company’s operations are financed through borrowed funds versus owner capital. The interest coverage ratio measures whether a company’s operating earnings are sufficient to cover its interest payments. CFOs and boards should pay particular attention to leverage, liquidity, debt maturities, and the quality of EBITDA, because a company that must sell negotiates from a very different position than a company that could sell, and optionality itself becomes an asset. A DSO that cannot articulate its leverage profile or refuses to share it signals a transparency problem.
Then clarify the equity model. With the capital structure in view, determine whether your rollover equity will be held at the parent-company level (diversified across all offices) or at the local joint-venture level (tied to your regional cluster). In a holdco model, the seller rolls into the parent DSO’s equity, so the return depends on the entire platform; in a joint venture model, the equity tracks a smaller, more local pool. Both structures have pros and cons, so you must know which one you are getting before signing.
Finally, review distribution history. Ask in writing: “What distributions have been paid to rolled sellers in the last 3 years?” If the buyer cannot answer questions about distribution history, when the next recapitalization is expected, or how dilution works, you may want to treat the rollover as worth close to zero.
What to Ask Dentists Who Sold to a DSO
The most reliable data usually comes from colleagues who have already lived through the transition, not from a corporate pitch deck. Effective peer due diligence benefits from structure and specificity.
Begin by requesting at least 3–4 reference calls. Ask the DSO to connect you with dentists who sold their practices 12–24 months ago, rather than only recent sellers still in the honeymoon phase. Dentists who have been through a full year of integration, a quality-of-earnings audit (the buyer’s independent verification of your practice’s EBITDA), and at least one performance review can often provide more candid information. Dentists should speak privately with dentists who sold to the prospective organization, ideally including doctors who have been there long enough for the initial transition period to pass, about appointment lengths, production expectations, turnover, treatment culture, and whether the organization fulfilled its commitments.
Once those calls are scheduled, ask specific, verifiable questions. When you get on the phone, avoid vague questions like “Are you happy?” and focus on concrete topics instead:
- Did the DSO alter staff benefits or compensation after closing?
- Did the DSO attempt to renegotiate your EBITDA during the quality-of-earnings audit?
- Were earnout targets realistic, or were they structured to be nearly impossible to hit?
- Did the DSO change your practice management software, labs, or supply vendors in the first 90 days?
- Who controls your daily schedule and appointment lengths?
- Would you do it again with the same DSO?
Then seek out dentists who left early. If possible, find dentists who sold to the DSO and subsequently departed before their work-back period ended. Sponsors that support office-level autonomy can produce better outcomes than sponsors that centralize aggressively. The reasons a dentist left early often reveal more about a DSO’s true culture than any marketing material.
DSO Deal Structure: Cash vs. Equity vs. Earnout
Headline enterprise value tells only part of the story in a DSO offer. DSOs often use complex structures that shift significant financial risk onto the seller, so understanding each component can be essential.
The only guaranteed piece of the deal is the cash you receive at close. In recent years, DSO deals commonly structure cash at close between 60% and 80% of headline enterprise value for lower-middle-market and platform transactions, with the lower end more common in specialty transactions or when the founder-doctor’s post-close clinical role is material. Because equity and earnouts depend on future performance, a lower cash percentage means more of your sale price sits at risk. For example, if a DSO offers 50% cash and 50% in equity and earnouts, you are taking on substantial risk that warrants careful modeling.
Understand the earnout mechanics. An earnout is a contingent payment made only if specified post-sale performance targets are met, typically over 1–3 years. Earnout risk sits almost entirely on the seller because the buyer controls operations post-close, and defensive terms worth negotiating include same-store EBITDA measurement, protection against buyer expense allocation, acceleration on change of control, and no gating on subjective metrics. Push for earnouts based on personal clinical production or total practice gross revenue, which are metrics you can directly influence and verify, rather than net profitability margins the DSO can alter through overhead allocations.
Evaluate the equity rollover realistically. Rollover equity of 10% to 30% is standard for platform and add-on DSO deals in recent years, with the upper end more common in platform-tier transactions requiring deeper alignment from founder-CEOs or key-doctor groups. Model the rollover in 3 scenarios, conservative, base, and upside, and discount the earnout for probability of achievement. Treat the rollover as a focused bet on the platform rather than as guaranteed value.
Review the work-back compensation. In a typical DSO acquisition, the selling dentist transitions from owner to associate, with clinical compensation shifting to 25–30% of collections. Calculate whether that rate adequately rewards your chairside time. Also review non-compete geographic radius and minimum production requirements that could trigger clawbacks if targets are missed.
Red Flags When Evaluating a DSO
Some warning signs warrant immediate caution, while others call for deeper investigation. To help you organize your assessment, the categories below group red flags into structural, behavioral, and regulatory types.
Structural red flags can include:
- An earnout-heavy offer where the buyer controls the inputs to the earnout calculation
- An EBITDA recast that you cannot audit or verify independently
- Vague clinical autonomy language that gives the DSO authority over “operational decisions” without clearly carving out clinical judgment
- Equity rollover with no distribution history and no clear path to liquidity
- Pressure tactics, such as an “exploding” LOI that gives you only days to sign
Behavioral red flags can include:
- Slow or selective document sharing during due diligence
- Reluctance to answer follow-up questions about financial health or ownership structure
- Refusal to connect you with dentists who sold 12–24 months ago
- Pressure to close quickly without adequate time for your own diligence
Regulatory red flags are worth monitoring closely. California’s SB 351, effective January 1, 2026, makes any contract provision that allows an investor-backed DSO to interfere with a dentist’s clinical judgment void, unenforceable, and against public policy. Colorado Dental Board regulations effective January 1, 2027 prohibit DSOs from holding the lease for a dental practice’s premises or owning equipment used at the practice. If a DSO’s management services agreement structure has drawn regulatory attention in any state, that situation can warrant serious scrutiny before you proceed.
Your DSO Vetting Scorecard: A Practical Framework
A structured scorecard helps you compare DSOs on the same criteria and keeps emotions from driving the decision. The table below shows 4 categories, each worth 25 points, and the red flag thresholds that can disqualify a DSO. Many sellers find the Capital & Ownership category the hardest area for getting clear, documented answers.
| Category (25 pts each) | Key Questions to Answer | What to Look For | Red Flag Threshold |
|---|---|---|---|
| Capital & Ownership | PE fund vintage year? Debt-to-equity ratio? Equity model (parent vs. JV)? Distribution history? | Transparent answers, documented leverage metrics, clear recapitalization timeline | Refusal to disclose ownership structure or leverage; no distribution history |
| Clinical Autonomy | Written protections in MSA and employment agreement? Control over scheduling, labs, materials? Regulatory compliance history? | Explicit written protections; verbal assurances at LOI mean nothing once definitive documents are signed | Vague “operational decisions” language; no written autonomy carve-outs |
| Deal Structure | Cash at close percentage? Earnout metrics and achievability? Equity rollover terms? Work-back compensation and non-compete scope? | Cash at close of 60–80%; earnout tied to auditable, seller-influenced metrics | Sub-60% cash; earnout based on metrics the buyer controls; no liquidity path for equity |
| Peer Due Diligence | Reference feedback from 3–4 dentists who sold 12–24 months ago? Staff retention post-close? EBITDA renegotiation during QoE? Overall satisfaction? | Consistent positive feedback on autonomy, staff treatment, and earnout fairness | Inability to provide references; reports of post-close renegotiation or staff disruption |
A DSO that scores below 70 out of 100 can warrant extreme caution. A DSO that refuses to provide information for any category often belongs off your shortlist.
Why Dental-Specific Sell-Side Representation Matters
Just as you would rely on a specialist for complex surgery, you should rely on dental-specific sell-side representation for a DSO deal.
McLerran & Associates has evaluated more than 10,000 practices and completed roughly 2,000 successful practice sales with approximately $2 billion in closed transaction volume. The firm runs a structured, auction-like bid process among a vetted pool of well-qualified buyers. This process typically takes 45–60 days and generates around 10 offers. Poorly run DSOs are blacklisted before they ever reach the table.
The numbers reflect the approach. McLerran & Associates reports a transaction rate of roughly 85–90%, versus an industry norm closer to 35–40%. Clients often receive around a 30% increase in valuation compared to selling alone. That improvement comes from controlling the narrative around your EBITDA and creating genuine competition among buyers.
Get help evaluating DSO offers and buyer quality with McLerran & Associates so you can see what your practice may be worth in both the private-buyer and DSO markets before you decide.
Frequently Asked Questions
How do I find out which private equity firm backs a DSO?
Ask directly during your initial conversations, and expect a clear answer. A legitimate DSO usually discloses its financial sponsor without hesitation. You can also review the DSO’s press releases and industry databases for ownership information. If a DSO is evasive about its ownership structure or the identity of its PE backer, that evasiveness can be a meaningful warning sign. Transparency about capital structure is a baseline expectation rather than an unreasonable demand. A dental-specific sell-side advisor like McLerran & Associates maintains ongoing relationships with vetted buyers and can often provide background on a DSO’s financial backing before you ever sit down at the table.
What is a PE fund vintage year and why does it matter to a dental practice seller?
A vintage year is the year a private equity fund began deploying capital into investments. Private equity funds typically have a total lifecycle of about 10 years, comprising a 3–5 year investment period and a 3–7 year harvest period, rather than a single 5–7 year investment cycle. If the fund backing your DSO is in years 4–5 of its cycle, a liquidity event, where you could potentially monetize your rolled equity, may be approaching. If the fund is early in its cycle, your rollover equity could be locked up for 5–7 years or longer with no clear path to liquidity. Knowing the vintage year helps you model the realistic timeline for your “second bite of the apple” and decide whether the equity component of the deal feels worth the wait and the risk.
Can clinical autonomy protections actually be negotiated into a DSO deal?
Clinical autonomy protections can often be negotiated, but the window to do so is narrow. These protections usually must be addressed before the Letter of Intent is signed, because once you enter the exclusivity period, typically 60–120 days, your leverage diminishes significantly. Protections worth pursuing in writing include treatment-planning autonomy, lab and material selection authority, scheduling-flow control for at least the first 12–18 months post-close, and veto rights over advertising and marketing. These provisions should appear explicitly in both the management services agreement and your employment agreement. Vague language giving the DSO authority over “operational decisions” without a clear carve-out for clinical judgment can invite future conflict. Verbal assurances from DSO representatives during pitch meetings carry no legal weight once definitive documents are signed.
What is a Quality of Earnings audit and how can it affect my deal price?
A Quality of Earnings audit, commonly called a QoE, is the buyer’s independent verification of your practice’s EBITDA. EBITDA means earnings before interest, taxes, depreciation, and amortization, and it is the profitability metric DSOs use to calculate your practice’s value. The QoE typically occurs after the Letter of Intent is signed and is the stage where deals most commonly get renegotiated downward. If your EBITDA was not properly documented and defended up front, the buyer’s QoE team will strip out unsupported add-backs, which are discretionary or non-recurring expenses added back to show true profitability, and reduce the purchase price accordingly. A reduction of even $200,000–$300,000 in documented EBITDA can translate to a price reduction of $1 million or more at typical DSO multiples. This dynamic is one reason a diligence-grade, CPA-led EBITDA analysis before going to market can be one of the most valuable investments a seller makes. McLerran & Associates builds this analysis up front so the numbers hold under scrutiny and the agreed value is less likely to be re-traded.
What should I do if I am not ready to sell but want to understand my options?
Getting educated before you commit can be a smart move. McLerran & Associates offers a complimentary practice valuation, a $2,500 value, to owners who attend the McLerran M&A Summit on October 29–30, 2026, in Austin. The Summit is built specifically for practice owners who have not yet decided whether to sell, to whom, or when. It covers deal structures, EBITDA fundamentals, the DSO and private equity landscape, and the doctor-to-doctor transition path, with no pressure to engage. If you prefer a one-on-one conversation first, McLerran will complete a comprehensive valuation and update it for free a year later if you are not ready to move forward. The goal is to help you make a major financial decision with full information rather than a guess.
Research First, Sell Smart
Selling your dental practice to a DSO can be one of the most consequential financial decisions of your career. The headline offer is only the beginning. The real question is whether the DSO behind that offer is a partner you can trust. Can you trust them with your equity? With your staff? With your patients and your legacy?
You can approach this decision like an investor. Analyze the private equity backing. Verify clinical autonomy claims in writing. Break the deal structure into its 3 components, cash, equity, and earnout, and model each honestly. Conduct rigorous peer due diligence with dentists who have been through the full integration experience. Use a scorecard to compare options objectively. Retain dental-specific sell-side representation that has guided thousands of doctors through similar decisions.
McLerran & Associates is the nation’s largest dental-specific sell-side M&A advisory firm and one of the few that runs both transition paths in roughly equal measure. The firm works exclusively for the seller, never the buyer. Its CPA-led EBITDA analysis helps control the narrative around your profitability. Its competitive bid process creates genuine market tension. As noted earlier, the firm’s track record includes roughly 2,000 successful sales, approximately $2 billion in transaction volume, and an 85–90% transaction rate.
Start your practice valuation with McLerran & Associates today. Call (512) 900-7989, email info@dentaltransitions.com, or visit our contact page. If you are still weighing your options, consider joining the McLerran M&A Summit on October 29–30, 2026, in Austin to get educated before you decide and receive a complimentary practice valuation, a $2,500 value.
